Status:
COMPLETED
Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Reactive Hypoglycemia
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.
Detailed Description
Symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion. Patients with this abnormality as an early manifestation of glucose intolerance are at higher risk of type 2 dia...
Eligibility Criteria
Inclusion
- Clinical and biochemical diagnosis of prediabetic reactive hypoglycemia
- Must be able to swallow tablet
- Negative pregnancy test (when appropriate)
Exclusion
- Renal insufficiency
- Hepatic insufficiency
- Diabetes (any type)
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00847080
Start Date
December 1 2008
End Date
March 1 2011
Last Update
April 26 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico City, Mexico, 14000